CN102028775A - Medicament or health-care food for preventing and treating chloasma and regulating immunologic function - Google Patents
Medicament or health-care food for preventing and treating chloasma and regulating immunologic function Download PDFInfo
- Publication number
- CN102028775A CN102028775A CN2010105922712A CN201010592271A CN102028775A CN 102028775 A CN102028775 A CN 102028775A CN 2010105922712 A CN2010105922712 A CN 2010105922712A CN 201010592271 A CN201010592271 A CN 201010592271A CN 102028775 A CN102028775 A CN 102028775A
- Authority
- CN
- China
- Prior art keywords
- chloasma
- preventing
- treating
- immunologic function
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 33
- 206010008570 Chloasma Diseases 0.000 title claims abstract description 24
- 208000003351 Melanosis Diseases 0.000 title claims abstract description 24
- 230000036737 immune function Effects 0.000 title claims abstract description 9
- 230000001105 regulatory effect Effects 0.000 title abstract description 5
- 235000013305 food Nutrition 0.000 title abstract 4
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 238000010992 reflux Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000013402 health food Nutrition 0.000 claims description 10
- 241000628997 Flos Species 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 6
- 241000698291 Rugosa Species 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000009636 Huang Qi Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 2
- 238000002474 experimental method Methods 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000000242 pagocytic effect Effects 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000003024 peritoneal macrophage Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000007306 turnover Effects 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 3
- 108010006464 Hemolysin Proteins Proteins 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000003228 hemolysin Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Abstract
The invention discloses a medicament or a health-care food for preventing and treating chloasma and regulating immunologic function. According to the knowledge of traditional Chinese medical science on the pathogeny of the chloasma, the medicament or the health-care food for preventing and treating the chloasma and regulating the immunologic function comprises active ingredients such as astragalus, Chinese angelica, root of red-rooted salvia and rose. Clinical experiments show that the medicament or the health-care food has good effect of removing the chloasma, can effectively regulate the immunity of human bodies, has high medicinal safety, and is suitable to be taken for a long time.
Description
Technical field
The present invention relates to field of medicaments, be specifically related to a kind of medicine or health food with the chloasma of preventing and treating and adjusting immunologic function.
Background technology
Chloasma is a kind of common intractable pigementation and increase dermatoses, and pilosity is born in the buccal position, and general long-term existence can initiatively not disappear.This disease sickness rate in the adult female is often followed endocrine disturbance and immunologic derangement up to 28.2%, has a strong impact on patient's face appearance and mental health.
The western medicine mechanism of chloasma morbidity at present is still indeterminate, thinks relevant with factors such as heredity, endocrine, immunity, gestation, illumination more, does not still have generally acknowledged good curing medicine.Discolor element or depigmentation preparation of external is the effective method of melanin increase in the treatment epidermis, but cures the symptoms, not the disease.
Modern Chinese medicine thinks that yin and yang imbalance in the human body: one because of depression of liver-QI, causes blood stasis face; Two because of weakness of the spleen and stomach, the QI and blood face of can not moistening, and the damp and hot face that rises to forms speckle; The three categories of etiologic factors insufficiency of kidney-YANG, the yang-energy disperse, blood stasis face, thus form chloasma.
Therefore, excavate motherland's Chinese medicine treasure-house, develop a kind of safe and effective medicine or health food of preventing and treating chloasma, will have great social significance and economic worth.
Summary of the invention
Technical problem solved by the invention is: according to the theory of Chinese medical science prescription, provide a kind of safe and effective medicine or health food of preventing and treating chloasma.
Medicine or the health food of preventing and treating chloasma of the present invention, the optimum weight proportioning of its functional component is: 6 parts of the Radixs Astragali, 3 parts of Radix Angelicae Sinensis, 9 parts of Radix Salviae Miltiorrhizaes, 3 parts of Flos Rosae Rugosaes.
Optimum extraction process of the present invention:
Get 6 kilograms of the Radixs Astragali, 3 kilograms of Radix Angelicae Sinensis, 9 kilograms of Radix Salviae Miltiorrhizaes, 3 kilograms of Flos Rosae Rugosaes, add 8 times of amount 70% alcohol reflux 1.5 hours, filter; Filtering residue adds 6 times of amount 70% alcohol reflux 1 hour, filters; Medicinal residues add 8 times of water gaging reflux, extract, 1.5h, filter.Merging filtrate concentrates, and drying is pulverized, and gets extract.
Consumption: need the oral medicine or the health food preparation that contain the extract that the above-mentioned technology of one thousandth weight portion makes the every day of generally being grown up.
Beneficial effect: the present invention can safe and effectively prevent and treat chloasma, has the effect of good adjusting immunity simultaneously.
Prescription mechanism: the present invention is according to the understanding of Chinese medicine to the chloasma cause of disease, adopt Radix Salviae Miltiorrhizae blood circulation promoting and blood stasis dispelling, nourishing blood to tranquillize the mind, Chinese angelica blood supplementing is invigorated blood circulation, the Flos Rosae Rugosae promoting QI circulation for relieving depression, relieving restlessness clears away heart-fire, Radix Astragali benefiting qi and raising yang, warming and invigorating the spleen and stomach, thereby realize the effect of blood circulation promoting and blood stasis dispelling, depressed liver-energy dispersing and QI regulating, warming YANG and invigorating QI, and then conditioning eliminating chloasma.
Below data illustrate beneficial effect of the present invention by experiment:
(1) the present invention treats the clinical research of chloasma effect
1, clinical data
Year May in February, 2008 to 2010, collect patient with chloasma 152 examples altogether, be the women, age 26-55 year; The course of disease 3 months to 12 years.Be divided into treatment group (83 example) and matched group (69 example) at random.
2, Therapeutic Method
The treatment group is taken the granule that the best prescription of invention medicine makes, and each 1 bag, every day 2 times, 2 months is 1 course of treatment; The oral stasis-resolving spot-removing sheet of matched group, one time 4,2 times on the one, 2 months is 1 course of treatment.
3, criterion of therapeutical effect
The clinical diagnosis and the curative effect determinate standard of the chloasma of formulating with reference to CAIM (Chinese Association Of Integrative Medicine) Dermatology Professional Committee pigment group are drafted.(1) the basic healing: naked eyes look the mottle area and disappear＞and 90%, color disappears substantially; (2) produce effects: naked eyes look the mottle area and disappear＞60% and≤90%, color is obviously thin out; (3) take a turn for the better: the mottle area disappears＞30% and≤60%, change color can perceive; (4) invalid: naked eyes look the mottle area and disappear≤and 30%, change color is not obvious.
4, experimental result gathers and sees Table 1
Table 1 liang group comprehensive therapeutic effect is [n (%)] relatively
Compare * P＜0.05 with matched group
Analyze experimental result, the total effective rate of treatment group is apparently higher than matched group, and basic cure rate and obvious effective rate are also apparently higher than matched group, two groups of cases there is no obvious adverse reaction during treating, the conscious spirit improvement of most of patient, energetic, show that the present invention can effectively treat chloasma, and drug safety is good.And find in the experimentation that the treatment group partly accompanies the patient of immunologic derangement, menoxenia when facial colour spot disappears, its simultaneous phenomenon has also obtained correspondingly improving.
On the basis of this discovery, we have further carried out the pharmacological research of the present invention to the body's immunity influence again.
(2) the present invention is to the pharmacological research of body's immunity influence
1, experimental technique
The female secondary mice of Kunming kind (body weight 18～22 grams) is adopted in experiment, carries out following experiment respectively: (1) delayed allergy (DTH)---toes swelling thickness method; (2) T lymphopoiesis functional examination---ConA stimulates the color reaction method (mtt assay) of changeing of drenching; (3) mensuration of NK cytoactive (lactic dehydrogenase enzyme process); (4) mensuration of antibody-producting cell; (5) mensuration of serum hemolysin (half hemolysis value algoscopy); (6) carbon is cleaned up exponential mensuration: carbon is cleaned up experiment; (7) Turnover of Mouse Peritoneal Macrophages is engulfed the chicken red blood cell experiment.
Experimental result adopts the SPSS13.0 statistical software to carry out statistical procedures.Data are all used " mean ± standard deviation
Expression is adopted variance analysis, inspection level α=0.05.
2, result
2.1 the experiment medicine aligns the influence of normal mice body weight, thymus/body weight, spleen/body weight and sees Table 2.
Table 2 couple normal mouse immune organ weight's influence
By table 2 as seen, compare each dosage group body weight, thymus/body weight, spleen/body weight there are no significant difference (P＞0.05) with matched group.
2.2 the experiment medicine aligns the influence of normal mice delayed allergy and sees Table 3.
The influence of table 3 pair normal mouse toes swelling thickness
Compare * P＜0.01 with matched group
By table 3 as seen, compare with matched group, the toes swelling thickness of middle and high dosage group significantly reduces (P＜0.01).
2.3 the experiment medicine aligns the influence of normal mice spleen lymphocytes proliferation ability and sees Table 4.
The influence of table 4 pair normal mouse spleen lymphocyte ConA multiplication capacity (
λ=570nm)
By table 4 as seen, compare with matched group, basic, normal, high dosage group all can significantly improve through the inductive spleen lymphocyte proliferation ability of ConA (P＜0.05).
2.4 the experiment medicine aligns the active influence of normal NK cells in mice and sees Table 5.
The table 5 pair active influence of normal NK cells in mice
Compare * P＜0.05 with matched group
By table 5 as seen, compare with matched group, the NK cytoactive of middle dosage group significantly improves (P＜0.05).
2.5 the experiment medicine aligns the influence of normal mouse antibodies cellulation (PFC) and sees Table 6.
The influence of table 6 couple normal mouse PFC
Compare * P＜0.05 with matched group
By table 6 as seen, compare with matched group, the PFC of middle dosage group significantly improves (P＜0.05).
2.6 the experiment medicine aligns the influence of normal mice serum hemolysin level and sees Table 7.
Table 7 couple normal mice serum HC
50The influence of level
Compare * P＜0.05 with matched group
By table 7 as seen, compare the HC of middle and high dosage group with matched group
50Significantly improve (P＜0.05).
2.7 the experiment medicine aligns the influence that normal mice carbon cleans up ability and sees Table 8.
The table 8 pair influence that normal mouse carbon is cleaned up
Compare * P＜0.05 with matched group
By table 8 as seen, compare with matched group, the carbon of middle and high dosage group is cleaned up index and is significantly improved.
2.8 engulfing chicken red blood cell test (half intracorporal method) to Turnover of Mouse Peritoneal Macrophages, the experiment medicine sees Table 9.
The influence of table 8 pair Turnover of Mouse Peritoneal Macrophages phagocytic activity
Compare P＜0.05 with matched group
By table 8 as seen, be subjected to the reagent object height, in, low dose group phagocytic rate, phagocytic index and normal control group relatively have significance to increase (P＜0.05).Illustrate and be subjected to the reagent thing to recommend to take the photograph the people and measure 10 times, 20 times, during 40 multiple doses, all have the effect that strengthens the Turnover of Mouse Peritoneal Macrophages phagocytic activity being equivalent to human body.
Analyze experimental result, the experiment medicine can reduce the toes swelling thickness of normal mouse, raising NK cytoactive, serum hemolysin level, antibody-producting cell quantity, carbon are cleaned up phagocytic index and macrophage phagocytic chicken red blood cell ability, and prompting experiment medicine has the function of regulating immunity of organism.
The specific embodiment
Embodiment 1:
Take by weighing the medical material of following weight proportion: 2 parts of the Radixs Astragali, 1 part of Radix Angelicae Sinensis, 2 parts of Radix Salviae Miltiorrhizaes, 1 part of Flos Rosae Rugosae, add 8 times of amount 70% alcohol reflux 1.5 hours, filter; Filtering residue adds 6 times of amount 70% alcohol reflux 1 hour, filters; Medicinal residues add 8 times of water gaging reflux, extract, 1.5h, filter.Merging filtrate concentrates, and adds 0.2 weight portion starch, 0.1 weight portion magnesium stearate, mixing, and granulation, tabletting get tablet.
Embodiment 2:
Take by weighing the medical material of following weight proportion: 35 parts of the Radixs Astragali, 15 parts of Radix Angelicae Sinensis, 20 parts of Radix Salviae Miltiorrhizaes, 8 parts of Flos Rosae Rugosaes, add 8 times of amount 70% alcohol reflux 1.5 hours, filter; Filtering residue adds 6 times of amount 70% alcohol reflux 1 hour, filters; Medicinal residues add 8 times of water gaging reflux, extract, 1.5h, filter.Merging filtrate concentrates, and drying is pulverized, and incapsulates shell, gets capsule.
Embodiment 3:
Take by weighing the medical material of following weight proportion: 6 parts of the Radixs Astragali, 3 parts of Radix Angelicae Sinensis, 9 parts of Radix Salviae Miltiorrhizaes, 3 parts of Flos Rosae Rugosaes, add 8 times of amount 70% alcohol reflux 1.5 hours, filter; Filtering residue adds 6 times of amount 70% alcohol reflux 1 hour, filters; Medicinal residues add 8 times of water gaging reflux, extract, 1.5h, filter.Merging filtrate concentrates, and drying is pulverized, and crosses 80 mesh sieves, adds dextrin 10 weight portions, steviosin 0.032 weight portion, and mixing is granulated, and drying gets granule.
Claims (4)
1. one kind has the chloasma of preventing and treating and regulates the medicine or the health food of immunologic function, it is characterized in that containing active ingredient: the Radix Astragali, Radix Angelicae Sinensis, Radix Salviae Miltiorrhizae, Flos Rosae Rugosae.
2. according to claim 1 have the chloasma of preventing and treating and regulate the medicine or the health food of immunologic function, it is characterized in that its weight proportion that contains each effective ingredient is: Radix Astragali 2-35 part, Radix Angelicae Sinensis 1-15 part, Radix Salviae Miltiorrhizae 2-20 part, Flos Rosae Rugosae 1-8 part.
3. according to claim 2 have the chloasma of preventing and treating and regulate the medicine or the health food of immunologic function, it is characterized in that its weight proportion that contains each effective ingredient is: 6 parts of the Radixs Astragali, 3 parts of Radix Angelicae Sinensis, 9 parts of Radix Salviae Miltiorrhizaes, 3 parts of Flos Rosae Rugosaes.
4. according to claim 2 or 3 described medicine or health foods, it is characterized in that its extraction process is: take by weighing above-mentioned medical material, add 8 times of amount 70% alcohol reflux 1.5 hours, filter with the chloasma of preventing and treating and adjusting immunologic function; Filtering residue adds 6 times of amount 70% alcohol reflux 1 hour, filters; Medicinal residues add 8 times of water gaging reflux, extract, 1.5h, filter, and merging filtrate concentrates, and drying gets extract.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010592271A CN102028775B (en) | 2010-12-14 | 2010-12-14 | Medicament or health-care food for preventing and treating chloasma and regulating immunologic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010592271A CN102028775B (en) | 2010-12-14 | 2010-12-14 | Medicament or health-care food for preventing and treating chloasma and regulating immunologic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102028775A true CN102028775A (en) | 2011-04-27 |
| CN102028775B CN102028775B (en) | 2012-08-29 |
Family
ID=43882585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010592271A Active CN102028775B (en) | 2010-12-14 | 2010-12-14 | Medicament or health-care food for preventing and treating chloasma and regulating immunologic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102028775B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389110A (en) * | 2011-11-02 | 2012-03-28 | 刘鹏 | Health product for treating chloasma |
| CN103212021A (en) * | 2013-03-26 | 2013-07-24 | 孙胜波 | Traditional Chinese medicine composition used for treating chloasma |
| CN103392985A (en) * | 2013-08-13 | 2013-11-20 | 汕头大学医学院第一附属医院 | Cake with rose flowers, angelica sinensis and astragalus mongholicus and preparation method thereof |
| CN107951951A (en) * | 2018-01-25 | 2018-04-24 | 向昌荣 | A kind of Chinese medicine composition for senile plaque expelling of dispelling and preparation method thereof |
| CN113975325A (en) * | 2021-10-29 | 2022-01-28 | 广东江门中医药职业学院 | Composition for invigorating qi and blood and preparation method and application thereof |
| CN114984156A (en) * | 2022-05-17 | 2022-09-02 | 成都中医药大学附属医院 | Pharmaceutical composition for treating chloasma |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513480A (en) * | 2009-04-07 | 2009-08-26 | 朱亚夫 | Pure traditional Chinese medicine composition for treating female sterility and pure traditional Chinese medicine preparation prepared thereby |
-
2010
- 2010-12-14 CN CN201010592271A patent/CN102028775B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101513480A (en) * | 2009-04-07 | 2009-08-26 | 朱亚夫 | Pure traditional Chinese medicine composition for treating female sterility and pure traditional Chinese medicine preparation prepared thereby |
Non-Patent Citations (1)
| Title |
|---|
| 李雪琳: "中西药内外合用治疗女性面部黄褐斑10例", 《中医外治杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389110A (en) * | 2011-11-02 | 2012-03-28 | 刘鹏 | Health product for treating chloasma |
| CN103212021A (en) * | 2013-03-26 | 2013-07-24 | 孙胜波 | Traditional Chinese medicine composition used for treating chloasma |
| CN103392985A (en) * | 2013-08-13 | 2013-11-20 | 汕头大学医学院第一附属医院 | Cake with rose flowers, angelica sinensis and astragalus mongholicus and preparation method thereof |
| CN107951951A (en) * | 2018-01-25 | 2018-04-24 | 向昌荣 | A kind of Chinese medicine composition for senile plaque expelling of dispelling and preparation method thereof |
| CN107951951B (en) * | 2018-01-25 | 2021-04-13 | 向昌荣 | Traditional Chinese medicine composition for removing senile plaques and preparation method thereof |
| CN113975325A (en) * | 2021-10-29 | 2022-01-28 | 广东江门中医药职业学院 | Composition for invigorating qi and blood and preparation method and application thereof |
| CN114984156A (en) * | 2022-05-17 | 2022-09-02 | 成都中医药大学附属医院 | Pharmaceutical composition for treating chloasma |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102028775B (en) | 2012-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102028775B (en) | Medicament or health-care food for preventing and treating chloasma and regulating immunologic function | |
| CN102198241B (en) | Medicine for alleviating nervousness and taking care of sub-health | |
| CN101797352B (en) | Chinese medicinal composition for treating lassitude hypodynamia and preparation method thereof | |
| CN100409883C (en) | Chinese medicinal composition for treating agrypnia, functional gastricism and astriction and its preparation method | |
| CN103405716A (en) | Herbal decoction for treating insomnia | |
| CN104998168B (en) | A kind of enriching the blood and tonifying qi herbal mixture lozenge and its preparation process | |
| CN102406831A (en) | Chinese medicine composition for treating insomnia and dreamful sleep and preparation method of Chinese medicine composition | |
| CN107715067B (en) | Pharmaceutical composition for conditioning blood stasis constitution and preparation method and application thereof | |
| CN102861201B (en) | Medicine composition for treating diabetes and preparation method thereof | |
| CN102631595A (en) | Medicament for treating II-type diabetes mellitus and preparation method thereof | |
| CN102698077A (en) | Traditional Chinese medicine composition for treating sub-health | |
| CN103948888A (en) | Traditional Chinese medicinal preparation for treating neurasthenia | |
| CN101549078A (en) | Pharmaceutical composition for treating intractable insomnia and preparation method thereof | |
| CN101167846A (en) | Capsule with blood sugar reducing function and preparation method thereof | |
| CN103599363A (en) | Traditional Chinese medicine combination for treating neurasthenia | |
| CN102132873A (en) | Medicine or health-care food for supplementing blood and regulating immunity | |
| CN103230457B (en) | A kind of Chinese medicine composition treating viral myocarditis and preparation method thereof and purposes | |
| CN103690780A (en) | Heart-invigorating and sedative pill and preparation method thereof | |
| CN102441103B (en) | Medicine for treating insomnia | |
| CN105477302A (en) | Insomnia treating traditional Chinese medicine composition and preparation method thereof | |
| CN111053882A (en) | Chinese herbal medicine preparation for treating leucoderma and preparation method thereof | |
| CN107137504B (en) | Health food for improving sleep and enhancing immunity | |
| CN101411770A (en) | Medicament for treating blood stasis accumulation type multiple sclerosis symptoms | |
| CN101411810B (en) | Medicament for treating multiple sclerosis symptoms | |
| CN101518575B (en) | Traditional Chinese medicine for treating diabetic insomnia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: KUANG DAIWU Effective date: 20131009 Owner name: YANTAI FUSHENGTANG HEALTH CARE PRODUCTS CO., LTD. Free format text: FORMER OWNER: YANTAI DAYANG PHARMACEUTICAL GROUP Effective date: 20131009 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20131009 Address after: 265500 Yantai, Fushan District, Shandong Telecom Road, No. 530 Patentee after: Yantai Fushengtang Health-care Products Co.,Ltd. Address before: 265500 Yantai, Fushan District, Shandong Telecom Road, No. 530 Patentee before: Yantai Dayang Pharmaceutical Co., Ltd. Patentee before: Kuang Daiwu |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170329 Address after: 264006 Shenzhen street, Yantai Development Zone, Shandong, No. 79 Patentee after: Kuang Daiwu Address before: 265500 Yantai, Fushan District, Shandong Telecom Road, No. 530 Patentee before: Yantai Fushengtang Health-care Products Co.,Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20180126 Address after: 264006 Shenzhen street, Yantai Development Zone, Shandong, No. 79 Patentee after: YANTAI BAOBEI BIOTECHNOLOGY CO., LTD. Address before: 264006 Shenzhen street, Yantai Development Zone, Shandong, No. 79 Patentee before: Kuang Daiwu |
|
| TR01 | Transfer of patent right |